glp-1 agonists reduce inflammation Frontiers Mechanisms by which GLP-1 agonists
Description
According to the World Health Organization (WHO), the global prevalence of obesity has nearly tripled since 1975
GLP-1 is a naturally occurring human hormone, released in the small intestine in response to food, that helps stabilize glucose levels

About the Author Dr

Medicare GLP-1 Bridge: A new federal demonstration program now provides select Medicare Part D beneficiaries access to Wegovy and Zepbound for a flat $50 monthly copayment , provided they meet specific medical criteria

Weight Loss Potential: Modest results, typically between 2 to 10 pounds

Future directions include the design and synthesis of novel compounds that can mitigate these side effects while maintaining or enhancing efficacy
